Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Enoblituzumab before Radical Prostatectomy versus Radical Prostatectomy Alone for the Treatment of High-Risk Localized Prostate Cancer

Trial Status: active

This phase II trial compares the effect of enoblituzumab before radical prostatectomy to radical prostatectomy alone in treating patients with high-risk prostate cancer that has not spread to other parts of the body (localized). Enoblituzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Enoblituzumab may block the activity of the B7 homolog 3 (B7-H3) pathway, which has been linked to aggressive prostate cancer and may drive disease progression. Currently, standard of care (SOC) treatment is a radical prostatectomy, which is surgery to remove the entire prostate. Patients with prostate cancer that has come back after a period of improvement (recurrence) that were treated with local therapies, such as a radical prostatectomy, are at a greater risk of the disease becoming metastatic (spreading to other places in the body). Giving enoblituzumab before undergoing radical prostatectomy may be more effective than surgery alone at delaying or preventing cancer recurrence in patients with high-risk localized prostate cancer.